Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Iron chelation: new therapies.

R Galanello1

  • 1Ospedale Regionale Microcitemie, Cagliari, Italy.

Seminars in Hematology
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

New oral iron chelator ICL 670A shows promise for treating iron overload. Unlike existing treatments, this computer-designed compound is well-tolerated and effective in early trials, offering hope for improved patient compliance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal analysis of heart and liver iron in thalassemia major patients according to chelation treatment.

Blood cells, molecules & diseases·2013
Same author

Relationship between neonatal screening results by HPLC and the number of α-thalassaemia gene mutations; consequences for the cut-off value.

Journal of medical screening·2011
Same author

Red cell pyruvate kinase deficiency in Southern Sardinia.

Blood cells, molecules & diseases·2010
Same author

Deferiprone chelation therapy for thalassemia major.

Acta haematologica·2009
Same author

The role of haemoglobin A(2) testing in the diagnosis of thalassaemias and related haemoglobinopathies.

Journal of clinical pathology·2008
Same author

Glutathione S-transferase gene polymorphism and cardiac iron overload in thalassaemia major.

British journal of haematology·2008

Area of Science:

  • Pharmacology
  • Hematology
  • Toxicology

Background:

  • Iron overload and toxicity pose significant health risks due to the lack of active iron excretion mechanisms.
  • Current iron chelator therapy, primarily deferoxamine, requires prolonged infusions, resulting in poor patient compliance.
  • Previous attempts to develop improved chelating agents have yielded disappointing clinical results.

Purpose of the Study:

  • To evaluate the efficacy and safety of ICL 670A, a novel, orally active iron chelator.
  • To assess the potential of ICL 670A as an alternative to existing iron chelation therapies.

Main Methods:

  • ICL 670A was designed using computer modeling as a potent and selective iron chelator.
  • Efficacy was demonstrated in animal models by its ability to mobilize tissue iron and promote excretion.

Related Experiment Videos

  • Phase I dose-finding trials assessed tolerability and safety in humans.

    • Main Results:

    • ICL 670A demonstrated potent and selective iron chelation capabilities in preclinical models.
    • Phase I clinical trials indicated that ICL 670A was well-tolerated with a favorable safety profile.
    • The compound effectively mobilizes tissue iron and promotes its excretion.

    Conclusions:

    • ICL 670A represents a promising new class of orally active iron chelators.
    • Its favorable safety and tolerability profile in early trials suggests potential for improved management of iron overload.
    • Further clinical evaluation is warranted to confirm its therapeutic benefits.